David L. Rimm, MD, PhD, is a Professor of Pathology and Professor of Medicine (Medical Oncology) at Yale School of Medicine-Yale University.

Posts

Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma

/in /by

Tumor-infiltrating lymphocytes (TILs) are a provocative biomarker in melanoma, influencing diagnosis, prognosis, and immunotherapy outcomes; however, traditional pathologistreadTIL assessment on hematoxylin and eosin–stained slides is prone to interobserver variability, leading to inconsistent clinical decisions. Therefore, development of newer TIL scoring approachesthat produce more reliable and consistent readouts is important.

Read more

Spatially Informed Gene Signatures for Response to Immunotherapy in Melanoma

/in /by

We aim to improve the prediction of response or resistance to immunotherapies in patients with melanoma. This goal is based on the hypothesis that current gene signatures predicting immunotherapy outcomes show only modest accuracy due to the lack of spatial information about cellular functions and molecular processes within tumors and their microenvironment.

Read more